Amphenol Corporation
—- Market cap
- $102.55B
- Debt
- —
- Cash
- −$11.13B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $102.55B · View financials
Snapshot Sep 11, 2026, 10:21 AM ET
Decision snapshot: APH stock price vs CTMX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTMX's multiple
Needs CTMX P/E.
Implied fair value · at APH's multiple
Needs Annual EPS.
Snapshot Sep 11, 2026, 10:22 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMPHENOL CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CytomX Therapeutics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
TE Connectivity plc
APH vs TEL
CORNING INC /NY
APH vs GLW
CommScope Holding Company, Inc.
APH vs COMM
HUBBELL INC
APH vs HUBB
BEL FUSE INC /NJ
APH vs BELFA
VISHAY INTERTECHNOLOGY INC
APH vs VSH
IDEAYA Biosciences, Inc.
APH vs IDYA
EXELIXIS, INC.
APH vs EXEL
GILEAD SCIENCES, INC.
APH vs GILD
AMGEN INC
APH vs AMGN
AbbVie Inc.
APH vs ABBV
BRISTOL MYERS SQUIBB CO
APH vs BMY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe APH can sustain its current profitability and growth profile, then the stock looks worth owning because it trades below CTMX-implied price while showing far stronger margins, earnings, and quality than CTMX.
APH trades below CTMX-implied price of $205.05, implying 24.6% upside versus the current price of $164.59. The valuation gap is influenced by APH’s stronger operating profile versus CTMX’s weak profitability and much smaller scale, even though APH is richer than its DCF range.
Supporting Metrics